IT / EN

Charcot-Marie-Tooth Type 2A (CMT2A) (Mitofusin 2)

CMT2A is an autosomal dominant hereditary axonal neuropathy, representing the most common form of axonal neuropathy (approximately 20% of all CMT2 cases). The pathology has an estimated prevalence of about 1–2 cases per 100,000 people, with significant clinical variability even among family members carrying the same mutation. Onset typically occurs during childhood or adolescence, characterized by progressive distal muscle weakness and atrophy, sensory involvement, and often early motor disability, making it generally more severe than other forms of CMT.

CMT2A is caused by mutations in the MFN2 gene (which encodes the Mitofusin 2 protein) located on chromosome 1p36.22.

Mitofusin 2 plays an essential role in mitochondrial fusion processes; it regulates the morphology and distribution of mitochondria within axons and maintains neuronal energy homeostasis. Mutations lead to mitochondrial dysfunction and energy deficits, resulting in a specific vulnerability of the longest axons.

Genetic Characteristics

Inheritance: Autosomal dominant.
Penetrance: High, estimated at 85-90%.
Expressivity: Highly variable (symptoms and severity can differ significantly even among family members).
De Novo Mutations: Approximately 10-15% of identified molecular defects are de novo mutations (occurring for the first time in a family member).

The symptoms of CMT2A manifest progressively and are often significantly more severe than other forms of neuropathy:

Motor Manifestations

Early Distal Muscle Weakness: Primarily affecting the feet and hands.
Gait Disturbances: Frequent falls, difficulty running, and a steppage gait (foot drop).
Pronounced Distal Muscle Atrophy: Visible wasting of the muscles in the lower legs and forearms.
Loss of Grip Strength: Progressively decreasing manual dexterity.
Late Proximal Involvement: Possible weakening of the thigh and shoulder muscles in advanced stages.

Characteristic Orthopedic Deformities

Severe Pes Cavus: High-arched feet, often more pronounced than in CMT1.
Hammer Toes: Claw-like positioning of the toes.
Scoliosis: More frequent in CMT2A than in other CMT subtypes.
Lumbar Hyperlordosis: Excessive inward curvature of the lower spine and joint contractures.

Sensory Symptoms

Sensory Loss: Reduced vibration and kinesthetic (position) sense.
Fine Touch Impairment: Loss of fine tactile sensitivity; possible neuropathic pain.
Areflexia: Reduction or total loss of deep tendon reflexes.

Phenotypic Variability

Severe Forms: Onset in early childhood, loss of independent walking (ambulation) before age 16, and potential respiratory involvement.
Moderate Forms: Adolescent onset with slower progression.
Atypical Manifestations: Possible involvement of the Central Nervous System (CNS) and Optic Nerve (optic atrophy).

Diagnostic Evaluation and Clinical Assessment

Clinical Evaluation: Detailed family history (confirming the autosomal dominant pattern) and a neurological examination focusing on distal weakness and muscle wasting.
Electroneurography (ENG): Characterized by preserved or only mildly reduced conduction velocities, but a severe reduction in action potential amplitude (classic axonal pattern).
Electromyography (EMG): Shows evidence of active and chronic denervation, signs of re-innervation, and a reduction in motor unit recruitment.
Advanced Imaging: Muscle MRI to detect fatty replacement (lipomatosis) of muscle tissue and quantitative ultrasound to assess the degree of atrophy.
Genetic Diagnosis: * First-line test: Sequencing of the MFN2 gene.
Broad approach: NGS (Next-Generation Sequencing) panels for hereditary neuropathies or mitochondrial diseases.
Family segregation analysis: If a causative variant is identified in the family index case.
Variant Interpretation: Over 100 pathogenic mutations have been described to date; however, there is limited genotype-phenotype correlation, meaning the specific mutation does not always predict the clinical severity.
Orthopedic Assessment: Clinical focus on characteristic foot deformities and continuous monitoring for the development of scoliosis.

Available therapies

Currently, there are no curative treatments for CMT2A; patient management is focused on symptomatic and rehabilitative care.

Specialized Orthopedic Management

Customized Foot Orthotics: To manage severe pes cavus and redistribute pressure.
Ankle-Foot Orthoses (AFOs): Essential for managing foot drop (steppage gait) and improving stability.
Early Corrective Surgery: Procedures such as osteotomies, arthrodesis, and surgical correction for scoliosis.
Regular Stretching: Crucial for preventing joint contractures and maintaining range of motion.

Specialized Rehabilitation

Targeted Physiotherapy: Selective muscle strengthening, balance and coordination exercises, and gait training.
Occupational Therapy: Adaptations for activities of daily living (ADLs), fine motor manipulation aids, and functional training.

Multidisciplinary Support

Regular Follow-up: Ongoing neurological, physiatric (rehabilitation medicine), and orthopedic monitoring.
Psychological Support: Counseling to manage the emotional impact of a progressive disability.
Complication Monitoring: Vigilance for secondary issues like respiratory involvement or skin breakdown on the feet.

Experimental Therapies and Research

Mitochondrial Dynamic Modulation: Investigating ways to fix the fusion/fission imbalance.
Gene Therapy: Approaches aimed at replacing or silencing the mutated MFN2 gene.
Neuroprotective Drugs: Small molecules intended to support axonal survival and energy production.

Research in progress

Gene Therapy and Research Frontiers for CMT2A

Ongoing research, notably supported by Fondazione Telethon, is focusing on innovative strategies to overcome the mitochondrial dysfunction caused by MFN2 mutations.

Therapeutic Strategies and Advanced Therapies
- MFN1 Expression Modulation: A key therapeutic strategy involving the upregulation of Mitofusin 1 (MFN1) to compensate for the functional loss of Mitofusin 2. Since both proteins are involved in mitochondrial fusion, boosting MFN1 can partially rescue the fusion defect in axons.
- Enhancement of Mitochondrial Function: Development of approaches to optimize energy production and mitochondrial health within the neuron.
- Advanced Modalities:
  - Gene Therapy: Delivering functional genetic material directly to target cells.
  - Antisense Oligonucleotides (ASOs): Molecules designed to modulate gene expression or silence the toxic effects of specific mutations.
  - Mitochondrial Metabolism Modulators: Pharmacological agents aimed at stabilizing the energetic output of the cell.
Research Models and Validation
- Experimental Models:
  - MFN2 Animal Models: To study disease progression and systemic response to treatment.
  - Neuronal Organoids: Derived from induced Pluripotent Stem Cells (iPSCs), allowing for the study of human-specific neuronal pathology in a “disease-in-a-dish” model.
  - Molecular Validation: Testing and validation of therapeutic molecules.
- Diagnostic and Functional Capacity: The center utilizes advanced techniques and reagents to assess the pathogenic impact of identified MFN2 variants. This includes validation in cells and tissues through:
  - Molecular and Biochemical methods.
  - Protein and Functional analysis.
- Global Collaboration: Active participation in international collaborations to facilitate experimental clinical trials.